CTC Bio, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Korea, Republic of (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2014
NCT02028598
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinical Trial Center North (CTC North GmbH & Co. KG) | CTC Bio, Inc. | CTC North GmbH & Co. KG Martinistrasse 64 20251 Hamburg Germany

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Diseases (Phase 3)

Coronavirus Infections (Phase 1)

Gastroesophageal Reflux (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 2)

Premature Birth (Phase 2)

Premature Ejaculation (Phase 2)

Rectal Neoplasms (Phase 2)

Stomach Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 25